Again, I agree. Of IPIX drugs Kevetrin is the furthest away from human use. Either path forward, going after modified (maybe with albumin linkage, who knows) IV compound having better half-life or developing oral extended release formulation will be time consuming and expensive. IPIX knows that currently it does not have resources to do either. Unfortunately so do prospective buyers.
News 
Market Data 
Discover 
